Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OsteoporeASX:OSX Cyclically Adjusted PS Ratio is 0.12 as of Sep. 16, 2026. The stock has 7 warning signs investors should review. Among 529 Medical Devices & Instruments companies, Osteopore ranks worse than 189035.73% on this metric.
Osteopore (ASX:OSX) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Osteopore Cyclically Adjusted PS Ratio Related Terms
Osteopore Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Osteopore's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:OSX vs ISRG, BDX, RMD: Cyclically Adjusted PS Ratio Comparison
For the Medical Instruments & Supplies subindustry, Osteopore's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Osteopore Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Osteopore's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Osteopore's Cyclically Adjusted PS Ratio falls into.
Osteopore Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Osteopore does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.
What does a Cyclically Adjusted PS Ratio of 0.12 mean?
Osteopore (ASX:OSX) has a Cyclically Adjusted PS Ratio of 0.12 as of Sep. 16, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Osteopore and its competitors. According to the industry distribution chart, Osteopore ranks #999999 out of 529 companies in the Medical Devices & Instruments industry.
Is Osteopore's Cyclically Adjusted PS Ratio too high?
Osteopore's current Cyclically Adjusted PS Ratio is 0.12. The Medical Devices & Instruments industry median Cyclically Adjusted PS Ratio is 2.22. Osteopore's value of 0.12 is 94.6% below this industry median. Based on the distribution chart, Osteopore ranks #999999 out of 529 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Osteopore's Cyclically Adjusted PS Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Osteopore ranks #999999 out of 529 companies for Cyclically Adjusted PS Ratio. This places Osteopore in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 2.22. Osteopore's value of 0.12 is 94.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Medical Devices & Instruments company?
The median Cyclically Adjusted PS Ratio among Medical Devices & Instruments companies is 2.22, based on 529 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Osteopore's current Cyclically Adjusted PS Ratio of 0.12 is 94.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Osteopore and its competitors. For the Medical Devices & Instruments industry, the median Cyclically Adjusted PS Ratio is 2.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Osteopore's current Cyclically Adjusted PS Ratio is 0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Osteopore stock overvalued right now?
Based on GuruFocus' analysis, Osteopore (ASX:OSX) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.01, compared to a current price of A$0.00 — trading 60% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 0.12 and 94.6% below the Medical Devices & Instruments industry median of 2.22. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Osteopore (ASX:OSX), the current Cyclically Adjusted PS Ratio is 0.12 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Osteopore Ltd is engaged in the production of 3D-printed bioresorbable implants that are used in conjunction with surgical procedures to assist bone healing. Its products include Osteoplug, which is a bioresorbable implant used for covering trephination burr holes in neurosurgery, and Osteomesh which is a bioresorbable implant used in craniofacial surgery. It operate in the high-growth regenerative medicine sector, where adoption continues to rise as healthcare systems increasingly embrace developed tissue-regenerative solutions. Business operating segments are based on the firm's geographical presence in Singapore and Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:OSX has been successfully added to your 
